A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Stopped This study was terminated due to limited efficacy and not due to safety reasons.

Conditions

• NUT Midline Carcinoma (NMC)
• Triple Negative Breast Cancer (TNBC)
• Non-small Cell Lung Cancer (NSCLC)
• Castration-resistant Prostate Cancer (CRPC)

Interventions

• DRUG: Birabresib

Sponsor

Merck Sharp & Dohme LLC